A Clear Guide to Regulation, Access and Oversight
In recent years, peptides have moved from research laboratories into broader clinical discussion. They are frequently mentioned in conversations about metabolism, tissue repair, ageing, and performance, often without much clarity around what they are, how they are regulated, or whether they are legally available in Australia.
We constantly have patients ask about them, so here's everything we know.
As with many emerging therapies, the detail matters.
If you are exploring information about peptide therapies in Australia, this guide outlines the current regulatory position, the role of the Therapeutic Goods Administration (TGA), and why clinical oversight is essential.
First, What Is a Peptide?
Peptides are short chains of amino acids — the building blocks of proteins. In the body, naturally occurring peptides function as signalling molecules. They help regulate processes such as:
Hormone release
Appetite signalling
Immune response
Tissue repair
Sleep and circadian rhythms
Some synthetic peptides have been developed for therapeutic purposes. Others remain experimental and are primarily studied in research settings.
The key distinction in Australia is not what a peptide does, but how it is regulated.
How Are Peptides Regulated in Australia?
In Australia, therapeutic goods are regulated under the Therapeutic Goods Act 1989 and overseen by the Therapeutic Goods Administration (TGA).
If a peptide is supplied for therapeutic use, it may fall into one of several regulatory categories:
1. Registered Medicines
Some peptide-based medicines are included on the Australian Register of Therapeutic Goods (ARTG). These products have undergone formal evaluation for safety, quality, and efficacy for specific indications.
You can search the ARTG here:
→ https://www.tga.gov.au/resources/artg
2. Prescription-Only Medicines (Unapproved Goods)
Many peptides discussed online are not registered on the ARTG. In some circumstances, they may be accessed through regulated pathways such as:
The Special Access Scheme (SAS)
The Authorised Prescriber Scheme
These pathways allow medical practitioners to prescribe certain unapproved therapeutic goods where clinically justified.
Further information is available from the TGA:
Special Access Scheme (SAS):
→ https://www.tga.gov.au/resources/resource/guidance/special-access-scheme-sas-guidance-health-practitioners
Authorised Prescriber Scheme:
→ https://www.tga.gov.au/resources/resource/guidance/authorised-prescriber-scheme
Importantly, access under these schemes is case-by-case and requires clinical justification. It is not a retail or over-the-counter pathway.
3. Research-Only Substances
Some peptides circulating online are described as “research chemicals” or labelled “not for human consumption.” These products may not be regulated as approved medicines and are not evaluated by the TGA for safety, quality, or efficacy.
Consumers should be aware that substances obtained outside regulated medical pathways may:
Not meet Australian manufacturing standards
Contain inconsistent or inaccurate dosing
Lack sterility testing
Be unlawfully supplied
The TGA provides guidance on unapproved therapeutic goods and regulatory obligations here:
→ https://www.tga.gov.au/products/unapproved-therapeutic-goods
Can Doctors Prescribe Peptides in Australia?
Whether a doctor can prescribe a specific peptide depends entirely on:
Its regulatory status
Its scheduling under the Poisons Standard
Whether it is registered or unapproved
The clinical indication
State and territory legislation
Some peptide-based medicines are Schedule 4 (Prescription Only Medicine) or Schedule 8 (Controlled Drug), meaning they require a valid prescription and are subject to state reporting requirements.
The Poisons Standard can be reviewed here:
→ https://www.tga.gov.au/publication/poisons-standard-susmp
If a peptide is not registered on the ARTG, access — where lawful — typically occurs through SAS or Authorised Prescriber pathways and must meet regulatory criteria.
Advertising Restrictions in Australia
Under Australian law, prescription medicines cannot be advertised directly to the public.
This includes most peptide therapies supplied via prescription.
The TGA outlines advertising restrictions here:
→ https://www.tga.gov.au/how-we-regulate/advertising
This regulatory position exists to ensure that decisions about prescription therapies occur within clinical consultation — not through promotional influence.
Why Clinical Oversight Matters
Peptides are biologically active compounds. Even when derived from naturally occurring molecules, synthetic versions may have pharmacological effects, contraindications, and potential risks.
Appropriate clinical oversight typically involves:
Detailed medical history review
Assessment of current medications
Consideration of evidence base
Discussion of known risks and uncertainties
Monitoring and follow-up
Because some peptides remain areas of emerging research, evidence strength varies significantly between products.
A cautious, evidence-aware approach is consistent with Australian regulatory standards.
Separating Hype from Regulation
Online discourse around peptides often outpaces regulatory clarity. It is not uncommon to encounter:
Claims unsupported by peer-reviewed evidence
Overseas practices that do not reflect Australian law
Direct-to-consumer marketing inconsistent with local regulation
In Australia, therapeutic use is governed by defined frameworks designed to protect patient safety.
The presence of discussion online does not automatically equate to lawful supply or established clinical indication.
A System Built on Structured Assessment
Australia’s regulatory model places responsibility on medical practitioners to:
Prescribe within scope
Comply with federal and state legislation
Use regulated access pathways where applicable
Maintain documentation and oversight
For individuals exploring peptide therapies, clarity begins with understanding this structure.
Appropriateness, where relevant, is determined through consultation — not through marketing claims or internet trends.
Further Reading
Therapeutic Goods Administration – Australian Register of Therapeutic Goods
https://www.tga.gov.au/resources/artg
Special Access Scheme Guidance
https://www.tga.gov.au/resources/resource/guidance/special-access-scheme-sas-guidance-health-practitioners
Authorised Prescriber Scheme
https://www.tga.gov.au/resources/resource/guidance/authorised-prescriber-scheme
Unapproved Therapeutic Goods
https://www.tga.gov.au/products/unapproved-therapeutic-goods
Poisons Standard
https://www.tga.gov.au/publication/poisons-standard-susmp
Advertising Therapeutic Goods
https://www.tga.gov.au/how-we-regulate/advertising
As with all prescription medicines in Australia, the appropriate starting point is a discussion with a qualified medical practitioner operating within the regulatory framework.
Emerging therapies require emerging conversations — guided by evidence, legislation, and clinical responsibility.
A Clear Guide to Regulation, Access and Oversight
In recent years, peptides have moved from research laboratories into broader clinical discussion. They are frequently mentioned in conversations about metabolism, tissue repair, ageing, and performance, often without much clarity around what they are, how they are regulated, or whether they are legally available in Australia.
We constantly have patients ask about them, so here's everything we know.
As with many emerging therapies, the detail matters.
If you are exploring information about peptide therapies in Australia, this guide outlines the current regulatory position, the role of the Therapeutic Goods Administration (TGA), and why clinical oversight is essential.
First, What Is a Peptide?
Peptides are short chains of amino acids — the building blocks of proteins. In the body, naturally occurring peptides function as signalling molecules. They help regulate processes such as:
Hormone release
Appetite signalling
Immune response
Tissue repair
Sleep and circadian rhythms
Some synthetic peptides have been developed for therapeutic purposes. Others remain experimental and are primarily studied in research settings.
The key distinction in Australia is not what a peptide does, but how it is regulated.
How Are Peptides Regulated in Australia?
In Australia, therapeutic goods are regulated under the Therapeutic Goods Act 1989 and overseen by the Therapeutic Goods Administration (TGA).
If a peptide is supplied for therapeutic use, it may fall into one of several regulatory categories:
1. Registered Medicines
Some peptide-based medicines are included on the Australian Register of Therapeutic Goods (ARTG). These products have undergone formal evaluation for safety, quality, and efficacy for specific indications.
You can search the ARTG here:
→ https://www.tga.gov.au/resources/artg
2. Prescription-Only Medicines (Unapproved Goods)
Many peptides discussed online are not registered on the ARTG. In some circumstances, they may be accessed through regulated pathways such as:
The Special Access Scheme (SAS)
The Authorised Prescriber Scheme
These pathways allow medical practitioners to prescribe certain unapproved therapeutic goods where clinically justified.
Further information is available from the TGA:
Special Access Scheme (SAS):
→ https://www.tga.gov.au/resources/resource/guidance/special-access-scheme-sas-guidance-health-practitioners
Authorised Prescriber Scheme:
→ https://www.tga.gov.au/resources/resource/guidance/authorised-prescriber-scheme
Importantly, access under these schemes is case-by-case and requires clinical justification. It is not a retail or over-the-counter pathway.
3. Research-Only Substances
Some peptides circulating online are described as “research chemicals” or labelled “not for human consumption.” These products may not be regulated as approved medicines and are not evaluated by the TGA for safety, quality, or efficacy.
Consumers should be aware that substances obtained outside regulated medical pathways may:
Not meet Australian manufacturing standards
Contain inconsistent or inaccurate dosing
Lack sterility testing
Be unlawfully supplied
The TGA provides guidance on unapproved therapeutic goods and regulatory obligations here:
→ https://www.tga.gov.au/products/unapproved-therapeutic-goods
Can Doctors Prescribe Peptides in Australia?
Whether a doctor can prescribe a specific peptide depends entirely on:
Its regulatory status
Its scheduling under the Poisons Standard
Whether it is registered or unapproved
The clinical indication
State and territory legislation
Some peptide-based medicines are Schedule 4 (Prescription Only Medicine) or Schedule 8 (Controlled Drug), meaning they require a valid prescription and are subject to state reporting requirements.
The Poisons Standard can be reviewed here:
→ https://www.tga.gov.au/publication/poisons-standard-susmp
If a peptide is not registered on the ARTG, access — where lawful — typically occurs through SAS or Authorised Prescriber pathways and must meet regulatory criteria.
Advertising Restrictions in Australia
Under Australian law, prescription medicines cannot be advertised directly to the public.
This includes most peptide therapies supplied via prescription.
The TGA outlines advertising restrictions here:
→ https://www.tga.gov.au/how-we-regulate/advertising
This regulatory position exists to ensure that decisions about prescription therapies occur within clinical consultation — not through promotional influence.
Why Clinical Oversight Matters
Peptides are biologically active compounds. Even when derived from naturally occurring molecules, synthetic versions may have pharmacological effects, contraindications, and potential risks.
Appropriate clinical oversight typically involves:
Detailed medical history review
Assessment of current medications
Consideration of evidence base
Discussion of known risks and uncertainties
Monitoring and follow-up
Because some peptides remain areas of emerging research, evidence strength varies significantly between products.
A cautious, evidence-aware approach is consistent with Australian regulatory standards.
Separating Hype from Regulation
Online discourse around peptides often outpaces regulatory clarity. It is not uncommon to encounter:
Claims unsupported by peer-reviewed evidence
Overseas practices that do not reflect Australian law
Direct-to-consumer marketing inconsistent with local regulation
In Australia, therapeutic use is governed by defined frameworks designed to protect patient safety.
The presence of discussion online does not automatically equate to lawful supply or established clinical indication.
A System Built on Structured Assessment
Australia’s regulatory model places responsibility on medical practitioners to:
Prescribe within scope
Comply with federal and state legislation
Use regulated access pathways where applicable
Maintain documentation and oversight
For individuals exploring peptide therapies, clarity begins with understanding this structure.
Appropriateness, where relevant, is determined through consultation — not through marketing claims or internet trends.
Further Reading
Therapeutic Goods Administration – Australian Register of Therapeutic Goods
https://www.tga.gov.au/resources/artg
Special Access Scheme Guidance
https://www.tga.gov.au/resources/resource/guidance/special-access-scheme-sas-guidance-health-practitioners
Authorised Prescriber Scheme
https://www.tga.gov.au/resources/resource/guidance/authorised-prescriber-scheme
Unapproved Therapeutic Goods
https://www.tga.gov.au/products/unapproved-therapeutic-goods
Poisons Standard
https://www.tga.gov.au/publication/poisons-standard-susmp
Advertising Therapeutic Goods
https://www.tga.gov.au/how-we-regulate/advertising
As with all prescription medicines in Australia, the appropriate starting point is a discussion with a qualified medical practitioner operating within the regulatory framework.
Emerging therapies require emerging conversations — guided by evidence, legislation, and clinical responsibility.
